Log in

Merck & Co., Inc. News Headlines (NYSE:MRK)

$84.52
-0.16 (-0.19 %)
(As of 10/22/2019 04:44 AM ET)
Today's Range
$84.08
Now: $84.52
$85.06
50-Day Range
$81.27
MA: $84.26
$86.67
52-Week Range
$66.10
Now: $84.52
$87.35
Volume5.13 million shs
Average Volume10.10 million shs
Market Capitalization$216.40 billion
P/E Ratio19.47
Dividend Yield2.60%
Beta0.53

Headlines

Merck & Co., Inc. (NYSE MRK) News Headlines

Source:
DateHeadline
Merck & Co., Inc. (MRK) to Release Quarterly Earnings on TuesdayMerck & Co., Inc. (MRK) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 22 at 2:47 AM
With $50M raise, Bedford startup seeks treatments for 75 percent of cancersWith $50M raise, Bedford startup seeks treatments for 75 percent of cancers
finance.yahoo.com - October 21 at 11:01 AM
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?
finance.yahoo.com - October 18 at 12:18 PM
Merck & Co., Inc.s (MRK) Buy Rating Reiterated at MizuhoMerck & Co., Inc.'s (MRK) Buy Rating Reiterated at Mizuho
www.americanbankingnews.com - October 18 at 11:41 AM
Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus DiseaseMerck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease
finance.yahoo.com - October 18 at 7:17 AM
Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell CarcinomaMerck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
finance.yahoo.com - October 18 at 7:17 AM
Merck to eliminate 500 jobsMerck to eliminate 500 jobs
finance.yahoo.com - October 17 at 2:03 PM
Zacks: Analysts Anticipate Merck & Co., Inc. (NYSE:MRK) Will Announce Quarterly Sales of $11.70 BillionZacks: Analysts Anticipate Merck & Co., Inc. (NYSE:MRK) Will Announce Quarterly Sales of $11.70 Billion
www.americanbankingnews.com - October 17 at 3:56 AM
Merck & Co., Inc. (NYSE:MRK) Now Covered by Bank of AmericaMerck & Co., Inc. (NYSE:MRK) Now Covered by Bank of America
www.americanbankingnews.com - October 16 at 5:58 PM
Zacks: Brokerages Expect Merck & Co., Inc. (NYSE:MRK) to Announce $1.25 EPSZacks: Brokerages Expect Merck & Co., Inc. (NYSE:MRK) to Announce $1.25 EPS
www.americanbankingnews.com - October 15 at 5:30 PM
Merck & Co., Inc. (NYSE:MRK) Short Interest UpdateMerck & Co., Inc. (NYSE:MRK) Short Interest Update
www.americanbankingnews.com - October 15 at 10:46 AM
Why Merck (MRK) is Poised to Beat Earnings Estimates AgainWhy Merck (MRK) is Poised to Beat Earnings Estimates Again
finance.yahoo.com - October 14 at 3:56 PM
Merck & Co., Inc. (NYSE:MRK) PT Set at $96.00 by JPMorgan Chase & Co.Merck & Co., Inc. (NYSE:MRK) PT Set at $96.00 by JPMorgan Chase & Co.
www.americanbankingnews.com - October 14 at 3:42 PM
Make sure you 'can pay for it': What health care execs think about Medicare for AllMake sure you 'can pay for it': What health care execs think about Medicare for All
finance.yahoo.com - October 13 at 3:27 PM
A cancer patient's journey to the cutting edge of cancer therapyA cancer patient's journey to the cutting edge of cancer therapy
finance.yahoo.com - October 11 at 5:41 PM
Pharma industry is 'right in the crosshairs,' Merck CEO Kenneth Frazier saysPharma industry is 'right in the crosshairs,' Merck CEO Kenneth Frazier says
finance.yahoo.com - October 10 at 1:31 PM
Merck CEO: Stepping down from Trump council was 'not a political issue'Merck CEO: Stepping down from Trump council was 'not a political issue'
finance.yahoo.com - October 10 at 1:31 PM
Seattle Genetics Up More Than 20% in 3 Months: Here's WhySeattle Genetics Up More Than 20% in 3 Months: Here's Why
finance.yahoo.com - October 10 at 1:31 PM
Merck (MRK) Stock Moves -1.33%: What You Should KnowMerck (MRK) Stock Moves -1.33%: What You Should Know
finance.yahoo.com - October 8 at 6:44 PM
Merck CEO Ken Frazier set to open Yahoo Finance's All Markets SummitMerck CEO Ken Frazier set to open Yahoo Finance's All Markets Summit
finance.yahoo.com - October 8 at 1:44 PM
BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast CancerBriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
finance.yahoo.com - October 7 at 8:55 AM
Merck KGaA completes acquisition of Versum MaterialsMerck KGaA completes acquisition of Versum Materials
finance.yahoo.com - October 7 at 8:55 AM
Whats Behind PDS Biotechs Rally?What's Behind PDS Biotech's Rally?
finance.yahoo.com - October 3 at 3:56 PM
Merck Sees Hammer Chart Pattern: Time to Buy?Merck Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - October 2 at 7:32 AM
FDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile InfectionsFDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections
finance.yahoo.com - October 2 at 7:32 AM
Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
finance.yahoo.com - October 2 at 7:32 AM
Merck (MRK) Stock Moves -0.68%: What You Should KnowMerck (MRK) Stock Moves -0.68%: What You Should Know
finance.yahoo.com - October 1 at 9:32 PM
Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29
finance.yahoo.com - October 1 at 7:50 AM
US Indexes Close Higher on the Last Day of SeptemberUS Indexes Close Higher on the Last Day of September
finance.yahoo.com - September 30 at 9:49 PM
AstraZeneca, Merck ovarian cancer treatment improves progression-free survivalAstraZeneca, Merck ovarian cancer treatment improves progression-free survival
uk.finance.yahoo.com - September 30 at 6:30 AM
Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 CongressFinal Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
finance.yahoo.com - September 29 at 3:17 AM
Merck & Co., Inc. (NYSE:MRK) Sees Large Decline in Short InterestMerck & Co., Inc. (NYSE:MRK) Sees Large Decline in Short Interest
www.americanbankingnews.com - September 28 at 2:05 PM
Pro Advisor: Buy Stocks Left In The Dust Instead Of IPOsPro Advisor: Buy Stocks 'Left In The Dust' Instead Of IPOs
finance.yahoo.com - September 26 at 5:44 PM
Menlo (MNLO) Completes Enrollment in Phase II Pruritus StudyMenlo (MNLO) Completes Enrollment in Phase II Pruritus Study
finance.yahoo.com - September 25 at 8:48 PM
Bristol-Myers' Opdivo Gains Positive CHMP View for New DoseBristol-Myers' Opdivo Gains Positive CHMP View for New Dose
finance.yahoo.com - September 25 at 3:48 PM
Merck (MRK) Dips More Than Broader Markets: What You Should KnowMerck (MRK) Dips More Than Broader Markets: What You Should Know
finance.yahoo.com - September 24 at 10:33 PM
Merck Financial Services GmbH -- Moodys announces completion of a periodic review of ratings of Merck KGaAMerck Financial Services GmbH -- Moody's announces completion of a periodic review of ratings of Merck KGaA
finance.yahoo.com - September 24 at 5:33 PM
Merck's Two HIV Drugs Get FDA Approval for Expanded UseMerck's Two HIV Drugs Get FDA Approval for Expanded Use
finance.yahoo.com - September 23 at 3:41 PM
Glaxo's Benlysta Gets Positive CHMP Opinion for Use in KidsGlaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids
finance.yahoo.com - September 23 at 3:41 PM
These 3 Long-Term Dividend Payers Offer a High Forward YieldThese 3 Long-Term Dividend Payers Offer a High Forward Yield
finance.yahoo.com - September 23 at 3:41 PM
UPDATE 1-Aid group says vaccine 'rationing' in Congo is hampering Ebola fightUPDATE 1-Aid group says vaccine 'rationing' in Congo is hampering Ebola fight
finance.yahoo.com - September 23 at 3:41 PM
US STOCKS-Wall St gains on stimulus cues, U.S.-China trade progressUS STOCKS-Wall St gains on stimulus cues, U.S.-China trade progress
finance.yahoo.com - September 21 at 8:11 PM
BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®
finance.yahoo.com - September 19 at 11:40 AM
Merck's Keytruda Combo Gets FDA Nod for Endometrial CarcinomaMerck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
finance.yahoo.com - September 18 at 12:33 PM
FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial CarcinomaFDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
finance.yahoo.com - September 17 at 10:41 PM
J&J Files sBLA for Tremfya With FDA for Psoriatic ArthritisJ&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
finance.yahoo.com - September 17 at 1:40 PM
Seattle Genetics' Enfortumab Vedotin BLA Gets Priority ReviewSeattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
finance.yahoo.com - September 17 at 1:40 PM
FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire VirusFDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
finance.yahoo.com - September 17 at 9:34 AM
A look inside Merck's new Peninsula research 'superhub'A look inside Merck's new Peninsula research 'superhub'
finance.yahoo.com - September 17 at 5:34 AM
Roche's New Perjeta Combo Meets Goal in Breast Cancer StudyRoche's New Perjeta Combo Meets Goal in Breast Cancer Study
finance.yahoo.com - September 13 at 8:12 PM
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel